RhumbLine Advisers’s Immuneering IMRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IMRX
DA
RhumbLine Advisers's IMRX Position: Q3 2026 in Review
RhumbLine Advisers increased its Immuneering (IMRX) stake by 0.26% in Q3 2026, buying an estimated $813 and bringing the position to 66,086 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #3100.
RhumbLine Advisers first reported a position in IMRX in Q1 2022 and has held it in 8 quarters since. The position peaked at $329K in Q2 2026. 131 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.
- RhumbLine Advisers held 66,086 shares of Immuneering worth $271K as of Q3 2026.
- RhumbLine Advisers bought 172 Immuneering shares in Q3 2026, an estimated $813.
- Immuneering made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3100 holding.
- RhumbLine Advisers first reported a position in Immuneering in Q1 2022 and has held it in 8 quarters since.
- RhumbLine Advisers's Immuneering position peaked at $329K in Q2 2026.
- 131 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.